Nkarta, INC Form 4 insider transactions

Chief Technical Officer Ralph Brandenberger reports acquisition of Nkarta, Inc. stock and options, according to a Form 4 filing.

Alicia J. Hager, Chief Legal Officer of Nkarta, Inc., reports the acquisition and disposal of common stock and stock options.

David Shook, Chief Medical Officer and Head of Research & Development at Nkarta, Inc., reports acquisition of shares and stock options.

Nadir Mahmood, President of Nkarta, Inc., reports the acquisition of 62,000 shares of common stock and options to purchase 123,500 shares, according to a Form 4 filing.

CEO Paul Hastings reports acquisition of restricted stock units and stock options, along with existing common stock holdings in Nkarta, Inc.

David Shook, Chief Medical Officer and Head of Research & Development at Nkarta, Inc., reports the sale of shares to cover tax obligations and discloses holdings including shares acquired through the employee stock purchase plan.

Nadir Mahmood, President of Nkarta, Inc., reports the acquisition of 550,000 stock options on July 29, 2024.

David Shook, Chief Medical Officer and Head of Research & Development at Nkarta, Inc., reports the acquisition of restricted stock units and stock options.

Alicia J. Hager, Chief Legal Officer of Nkarta, Inc., reports the sale of 3,396 shares of common stock at $8 per share on July 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

James Trager, Chief Scientific Officer of Nkarta, Inc., sold 456 shares of common stock on June 18, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Nkarta's CEO, Paul Hastings, sold 1,770 shares of common stock on June 18, 2024, to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

David Shook, Chief Medical Officer of Nkarta, Inc., sold 456 shares of common stock on June 18, 2024, to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Alicia Hager, Chief Legal Officer of Nkarta, Inc., sold 727 shares of common stock on June 18, 2024, to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Ralph Brandenberger, Chief Technical Officer of Nkarta, Inc., sold 229 shares of common stock on June 18, 2024, to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Director Simeon George acquired 22,500 stock options in Nkarta, Inc. on June 13, 2024.

Director Ali Behbahani acquired 22,500 stock options in Nkarta, Inc. on June 13, 2024, vesting on the earlier of June 13, 2025, or the first annual meeting after the grant date.

RA Capital Management and related entities report changes in beneficial ownership of Nkarta, Inc. stock, including the grant of a stock option to Dr. Zachary Scheiner.

Director Zachary Scheiner acquired stock options for Nkarta, Inc., though disclaims beneficial ownership due to an arrangement with RA Capital Management.

Director Patterson Leone D acquired 22,500 stock options in Nkarta, Inc. on June 13, 2024, according to a Form 4 filing.

Director Michael Dybbs acquired 22,500 stock options in Nkarta, Inc. on June 13, 2024.

Director Angela Thedinga acquired 22,500 stock options in Nkarta, Inc. on June 13, 2024, according to a Form 4 filing.

Director George Vratsanos acquired 45,000 stock options in Nkarta, Inc. on June 13, 2024, according to a Form 4 filing with the SEC.

RA Capital Management and related entities acquired 3,000,000 shares of Nkarta, Inc. common stock and pre-funded warrants to purchase an additional 3,000,031 shares for a total investment of $30 million.

Director Simeon George reports indirect acquisition of Nkarta, Inc. shares through a public offering at $10 per share.

Nkarta's CEO, Paul Hastings, executed sales of common stock on March 1st and 4th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Ralph Brandenberger, Chief Technical Officer of Nkarta, Inc., executed stock option exercises and sales under a pre-arranged Rule 10b5-1 trading plan.